Pain is an unpleasant sensation that is part of the body’s protective mechanism designed to give a warning of potential or actual tissue damage. When pain is not managed effectively, it can persist and become debilitating, resulting in an overwhelming burden of suffering and poor quality of life. Due to the complexity of chronic pain, the Seeker is seeking proposals for alternative cell-based/gene editing approaches to deliver more effective therapies.
This is an electronic Request-for-Partners (eRFP) Challenge; the Solver will only need to submit a written proposal to be evaluated by the Seeker with the goal of establishing a collaborative partnership.
Across the globe, chronic pain is a source of considerable suffering and disability, with significant economic, physical, psychological, and social consequences. Chronic pain can be associated with an injury or disease, but in other cases, there may be no clear cause. Although moderate to severe pain can be relieved with prescription pain relievers, misuse and addiction to opioids is a growing problem. The Seeker is committed to pain research and providing innovative and reliable medications for patients. Successful proposals will include compelling evidence of potent and reproducible pain modulation.
This is an electronic Request-for-Partners (eRFP) Challenge. The Solver will write a preliminary proposal (maximum of 10 pages, not including references and contact details) to be evaluated by the Seeker with a goal of establishing a collaborative partnership. Upon completion of the evaluation, the Seeker may contact selected Solvers directly to work out terms for a collaboration contract. The monetary value of the contract will vary depending on the amount of work to be delivered and the agreed time frame.
[NOTE: Only proposals from Solvers who have the ability to work as a collaboration partner will be considered.]
Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on June 30, 2019.
Late submissions will not be considered.
ABOUT THE SEEKER
The Grünenthal Group: http://www.grunenthal.com/
The Grünenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation.
We are a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. By sustainably investing in our R&D above the industrial average, we are strongly committed to innovation.
In Grünenthal Innovation, we are strongly driven to seek new solutions for patients with severe diseases and high unserved medical need – and make these solutions accessible to patients. We combine an entrepreneurial spirit and our best-in-class science & technology approaches with excellence in execution.
With our fully integrated R&D and networked approach we combine the best of two worlds: we discover and develop new chemical entities (NCEs) and new technology platforms in-house. At the same time, we access external innovation and knowledge – and are courageous to exploit new paths.
Innovation is more than just the identification and development of a NCE. We believe innovation involves the combination of approaches including identifying new/different drug modalities, technologies and ways to optimize data handling to bring new therapies to patients.
What is an eRFP Challenge?
eRFPs allow Seekers to submit Requests for Proposals for a partner or supplier to provide materials or expertise to help solve a business challenge to the InnoCentive Solver community. This global community includes organizations and individuals, such as contract research organizations, scientists, university researchers, and technology companies.
After a Solver submits an eRFP response, the Seeker evaluates the responses to determine which Solver(s) to contact for further business discussions. With eRFPs, the Solver must not provide any confidential information in the eRFP response. If your eRFP response is selected, you negotiate the terms of the contract (including scope of work, tasks and duration) directly with the Seeker.
This Challenge type does not require Intellectual Property (IP) transfer. However, sometimes Challenges of this type do request that certain IP arrangements be made should a partnership be formed.